Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4658 in healthy volunteers or volunteers with elevated blood pressure
NCT07230145Phase 1Not yet recruiting
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) and hypertension (HTN) comparing SHR-4658 Group with Placebo Group (2 arms). Primary endpoint: Adverse events (AEs) at 16 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SHR-4658
03
Conditions
heart failure (HF)hypertension (HTN)
Beyond the preview
Go deeper on NCT07230145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230145.